In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
Quiz|Articles|May 1, 2026
OncLive Weekly News Quiz (5/1/2026): Are You Caught Up on 2 FDA ODAC Votes in Prostate and Breast Cancer?
Author(s)OncLive Staff
Fact checked by: Chris Ryan
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
How did the FDA’s Oncologic Drugs Advisory Committee (ODAC) vote on capivasertib (Truqap) plus abiraterone acetate (Zytiga) based on findings from the phase 3 CAPItello-281 trial (NCT04493853) in PTEN-deficient metastatic hormone-sensitive prostate cancer; and on switching to camizestrant based data from the phase 3 SERENA-6 trial (NCT04964934) in ESR1-mutant, hormone receptor–positive metastatic breast cancer?
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
The FDA approved iberdomide plus daratumumab and dexamethasone for relapsed/refractory multiple myeloma.
Zipalertinib plus chemotherapy produced a statistically significant, clinically meaningful PFS improvement vs chemotherapy alone at a planned interim analysis.
Michael J. Morris, MD, discusses the FDA approval of lutetium Lu 177 vipivotide tetraxetan plus an ARPI in PSMA+ mHSPC.
T-DXd plus pertuzumab was approved in China as first-line treatment for unresectable or metastatic HER2-positive breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
Fixed-Duration Acalabrutinib/Venetoclax Regimens Shows Similar Safety Across Age Groups in Treatment-Naive CLL
2
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
3
Zipalertinib Plus Chemotherapy Improves PFS in First-Line EGFR Exon 20 Insertion+ NSCLC
4
Dr Van Gorp on PFS Data With TUB-040 in Platinum-Resistant Ovarian Cancer
5